Prospective Evaluation of Clinical Outcomes Using a Multiplex Liquid Biopsy Targeting Diverse Resistance Mechanisms in Metastatic Prostate Cancer.

Jamie M Sperger Hamid Emamekhoo Rana R McKay Charlotte N StahlfeldAnupama SinghXinyi E ChenLucia KwakCole S GilsdorfSerena K WolfeXiao X WeiRebecca SilverZhenwei ZhangMichael J MorrisGlenn BubleyFelix Y FengHoward I ScherDana RathkopfScott M DehmToni K Choueiri Susan Halabi Andrew J Armstrong Alexander W WyattMary-Ellen TaplinShuang G ZhaoJoshua M Lang

Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)

We demonstrate that a transcriptional profile detectable in CTCs obtained from liquid biopsies can serve as an independent prognostic marker beyond AR-V7 in patients with metastatic prostate cancer and can be used to identify the emergence of multiple ARSI resistance mechanisms. This is currently being investigated in additional prospective trials.

Keyphrases

prostate cancer
radical prostatectomy
ionic liquid
ultrasound guided
squamous cell carcinoma
small cell lung cancer
circulating tumor cells
gene expression
high throughput
cancer therapy
oxidative stress
drug delivery
single cell
heat stress